SEC Form DEFA14A filed by QuidelOrtho Corporation

4/8/25 4:06:30 PM ET

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Health Care

DEFA14A 1 fy24defa14-a.htm DEFA14A Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No. )

Filed by the Registrant ý

Filed by a Party other than the Registrant ¨

Check the appropriate box:


¨						Preliminary Proxy Statement

¨						Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

¨						Definitive Proxy Statement

ý						Definitive Additional Materials

¨						Soliciting Material Pursuant to §240.14a-12

QUIDELORTHO CORPORATION

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

No fee required.

Fee paid previously with preliminary materials.

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

Date	Price Target	Rating	Analyst
5/8/2025	$44.00	Hold → Buy	Jefferies
12/11/2024	$44.00 → $50.00	Neutral → Buy	Citigroup
12/10/2024	$43.00	Hold	Jefferies
9/19/2024	$42.00 → $50.00	Neutral	UBS
9/5/2024	$40.00 → $57.00	Hold → Buy	Craig Hallum
3/4/2024	$70.00 → $42.00	Neutral → Sell	UBS
2/14/2024	$66.00 → $37.00	Neutral → Underweight	JP Morgan
12/11/2023	$95.00 → $72.00	Buy → Neutral	Citigroup

Recent Analyst Ratings for
$QDEL